Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

3322 - Prognostic implication of inflammation-based scores in patients with metastatic pancreatic cancer (mPC) treated with first-line nab-paclitaxel plus gemcitabine (AG)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cytotoxic Therapy

Tumour Site

Pancreatic Adenocarcinoma

Presenters

Inhwan Hwang

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

I. Hwang1, J. Kang2, C. Yoo1, J.H. Jeong1, K. Kim1, H. Chang1, B. Ryoo1

Author affiliations

  • 1 Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, 138-736 - Seoul/KR
  • 2 Oncology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, 03181 - Seoul/KR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3322

Background

AG is standard first-line chemotherapy for patients with mPC. However, prognostic factors for patients with mPC treated with AG are largely unknown. This retrospective analysis was performed to identify the prognostic factors including inflammation-based prognostic scores in mPC patients treated with AG as first-line treatment.

Methods

A total of 203 patients with histologically confirmed recurrent (n = 55) or metastatic (n = 148) pancreatic cancer who were treated with first-line AG in Asan Medical Center, Seoul, Korea, between January 2013 and January 2018, were included in this analysis. As inflammation-based scores, baseline Neutrophil-lymphocyte ratio (NLR), Platelet-lymphocyte ratio (PLR) and modified Glasgow prognostic score (mGPS) were tested. Cox-proportional hazards model were used to identify prognostic factors in univariate and multivariate analyses.

Results

Median age was 62 years (range, 32-82) and 116 patients (57%) were male. With median follow-up duration of 21.5 months (range, 0.5-34.3), median overall survival (OS) and progression-free survival (PFS) in overall patients were 15.1 (95% CI 12.6-17.6) and 7.1 (95% CI, 6.2-8.0) months, respectively. In multivariate analysis, elevated CA19-9 level (HR 1.75, p = 0.008), liver metastasis (HR 1.8, p = 0.001), distant lymph node metastasis (HR 1.4, p = 0.04), and high mGPS (≥1 vs.0: HR 1.6, p = 0.005) were significantly associated with poorer OS. For PFS, poor performance status (PS) (ECOG PS ≥ 2 vs 0/1: HR 2.1, p = 0.048), liver metastasis (HR 1.4, p = 0.03), distant lymph node metastasis (HR 1.5, p = 0.02), and elevated CA 19-9 level (HR 1.1, p = 0.02) were significantly related with poorer outcomes. Neither NLR nor PLR was significantly associated with PFS or OS.

Conclusions

CA 19-9 level, liver and distant lymph node metastasis were independent prognostic factors in mPC patients treated with first-line AG. Among the inflammation based prognostic scores, mGPS may be the reliable indicator for the prediction of OS.

Clinical trial identification

Legal entity responsible for the study

Asan Medical Center.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.